Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers discover that a virus can naturally target and kill tumors

02.02.2004


Gene therapy techniques enhance the virus’s effectiveness in mice.



Mosquitoes are notorious for their ability to spread disease, but in some cases they may prove to be a boon instead of a bane. In a recent study, researchers at New York University School of Medicine found that one mosquito-borne virus automatically targets and kills tumor cells in mice. Most importantly, it does so while leaving healthy cells alone, a feature that may make it a promising treatment for some forms of cancer.

This study involved tumors in mice, and the virus has yet to be tested in humans. Daniel Meruelo, Ph.D., Professor of Pathology at NYU School of Medicine and principal investigator of the study, hopes to begin clinical trials of the virus within about two years. But he stresses that there is still far more work to be done before the virus can be shown to be safe for human application, let alone an effective treatment for human tumors. Mice and humans can respond differently to viruses, he notes.


According to the study, published in the January 2004 issue of the journal Nature Biotechnology, the Sindbis virus is effective at killing tumors in mice at every location tested--whether the growths occur under the skin, in the pancreas, in the main body cavity, or in the lungs.

The amount of time and the number of injections needed to cause tumor remission varied, depending on the type of cancer, but in general mice were given injections of the virus daily. Within a month to two months later, many tumors disappeared completely.

The virus, named Sindbis after the Egyptian town where it was first identified, is found in many parts of Asia and Africa. It is carried and transmitted exclusively by mosquitoes, which bite and infect humans and other animals. In humans, the virus causes cold-like symptoms, such as fever and muscle ache, which quickly subside.

Viruses aren’t usually thought of as beneficial, but in recent years scientists have started to take advantage of the ability of viruses to infiltrate human cells, enlisting these infectious agents to treat disease. Most of these viruses have been genetically engineered so that they will not cause disease, but will infect rapidly dividing cancer cells. At least 10 different oncolytic, or cancer-killing, viruses are in early clinical trials.

Sindbis is different from these other cancer-killing viruses in that most of the others have to undergo some kind of genetic manipulation to target cancer cells, and they also have to be injected directly into tumors. The NYU School of Medicine team found that Sindbis requires no such manipulation to be effective, and it can apparently be injected anywhere into mice but still find its way through the bloodstream unscathed to the target area.

"Nature gave us a gift in Sindbis," says Dr Meruelo. "It has a natural ability to infect tumor cells almost exclusively, and naturally induces cell death in these tumor cells."

This relatively mild-mannered virus first came under scientific scrutiny as a potential vehicle for gene therapy, where modified viruses are used to ferry genetic treatments into cells. But the unmodified virus, without added genes, surprised Dr. Meruelo and his colleagues. They found that it was quite successful at killing tumor cells all on its own. "We realized the natural, unmodified Sindbis was working beautifully so we decided to examine that more carefully," says Dr. Meruelo.

Since Sindbis is a virus, the researchers were concerned that the immune system might attack it, thwarting any therapeutic effect. However, tests on genetically modified mice, which grow tumors but have fully working immune systems, were also successful.

To build upon Sindbis’s natural cancer-killing skills, Dr. Meruelo and his colleagues also engineered the virus to carry a gene that makes a protein called IL-12. This protein has proven to be a good cancer killer but is also toxic to normal tissues. By putting the IL-12 gene into Sindbis, the gene was only activated after it had been carried into cancerous tissues by the virus. The combination was even more effective than Sindbis alone at killing tumors, and it did not poison surrounding areas.

It is not known exactly why the virus prefers to bind to tumor cells. But Sindbis enters cells through a receptor for laminin, a substance that helps to glue cells together to form tissues, and tumor cells tend to over-express this receptor. Dr. Meruelo theorizes that since tumor cells are far more likely than healthy cells to have free laminin receptors on their surfaces, they are more likely to take up the virus.

The virus may also be a good tracking device for cancer. Dr. Meruelo and his colleagues attached to Sindbis a gene that makes fireflies glow, which was only activated in cells that the virus entered, making them glow enough to be detected by an external sensor. "We showed that we knew exactly where the virus was, and the virus was only in the tumors," says Dr. Meruelo.

Despite the need to demonstrate the virus’s effectiveness in humans, Dr. Meruelo is hopeful about Sindbis’s future: "The combination of this virus’s exquisite targeting of tumors with its ability to kill them says that this has the potential to be a human therapy."


The other authors of the study at NYU School of Medicine are Herman Yee, M.D., Ph.D., Assistant Professor of Pathology, Peter Shamamian, M.D., Associate Professor of Surgery, Richard P. Novick, M.D. Professor of Microbiology and Medicine, Angel Pellicer, M.D., Ph. D., Professor of Pathology, Jen-Chieh Tseng, graduate student and first author, Brandi Levin, supervisory research technician in Pathology, Alicia Hurtado, Assistant Research Scientist in Pathology, and Ruzhong Jin, graduate student. Authors Ignacio Perez de Castro and Maria Jimenez are former fellows who are now at the National Center of Oncology in Madrid, Spain.

Pam McDonnell | EurekAlert!
Further information:
http://www.med.nyu.edu/

More articles from Life Sciences:

nachricht The birth of a new protein
20.10.2017 | University of Arizona

nachricht Building New Moss Factories
20.10.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>